心脏PET显像在结节病患者中的预后作用:系统综述
该系统综述检索MEDLINE至2020年10月,纳入6项回顾性观察研究共515例疑诊或确诊心脏结节病患者,评估基线FDG PET异常对MACE的预后价值。平均随访1.4至4.1年共发生105例MACE,5项研究显示FDG PET与主要结局呈正向预后关联,但证据仍需进一步量化。
要点
- 基线FDG PET异常(局灶或局灶叠加弥漫摄取,或伴灌注缺损)与心脏结节病患者MACE风险相关。
- 6项研究均为回顾性观察设计,全部报告MACE复合终点,其中4项进行调整分析。
- 现有证据支持FDG PET用于心脏结节病风险分层,但仍需更多研究量化其效应。
核心结论
- 现有证据提示FDG PET可用于心脏结节病患者的风险分层,但仍需进一步研究量化该患者群体中的效应。
研究设计与样本
- 系统综述,检索MEDLINE自建库至2020年10月,纳入6项机构来源的回顾性观察研究,共515例患者,53.4%为女性,19.8%为少数族裔。
主要发现
- 平均随访1.4至4.1年,共发生105例MACE,所有研究均将死亡(全因死亡或心源性猝死)和室性心律失常(室性心动过速或心室颤动)作为MACE组分。
- 6项研究均采用PET定性评估(异常FDG摄取伴或不伴灌注异常),2项研究评估了定量指标(异常FDG摄取节段的 summed stress score、标准化摄取值和心脏代谢活性)。
- 5项研究发现FDG PET与主要结局呈正向预后关联,其中2项评估了右心室摄取。
关键数值与推荐
- 异常PET定义为代谢异常(存在FDG局灶或局灶叠加弥漫摄取)或代谢异常伴灌注缺损。
- 6项研究均报告MACE复合终点;4项研究进行调整分析,均使用左心室射血分数(LVEF),其他调整变量各研究间不一致。
临床怎么用
- 对疑诊或确诊心脏结节病患者,可考虑基线FDG PET显像(定性评估异常FDG摄取伴或不伴灌注异常)辅助MACE风险分层。
局限性
- 纳入研究均为回顾性观察设计,样本量有限(共515例),调整变量不一致,定量指标仅2项研究评估,效应量尚需进一步研究量化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sarcoidosis is a multi-systemic inflammatory disease of unknown etiology. Cardiac sarcoidosis (CS) has been reported in as much as 25% of patients with systemic involvement. 18Fluorodeoxyglucose (FDG) positron emission tomography (PET) has a high diagnostic sensitivity/specificity in the diagnosis of CS. The aim of this review is to summarize evidence on the prognostic role of FDG PET. METHODS: Studies were identified by searching MEDLINE from inception to October 2020. Medical subject headings (MeSH) terms for sarcoidosis; cardiac and FDG PET imaging were used. Studies of any design assessing the prognostic role of FDG PET in patients with either suspected or confirmed cardiac sarcoidosis imaging done at baseline were included. Abnormal PET was defined as abnormal metabolism (presence of focal or focal-on-diffuse uptake of FDG) OR abnormal metabolism and a perfusion defect. Studies reporting any outcome measure were included. Pooled risk ratio for the composite outcome of MACE was done. RESULTS: A total of 6 studies were selected for final inclusion (515 patients, 53.4% women, 19.8% racial minorities.) Studies were institution based, retrospective in design and enrolled consecutive patients. All were observational in nature and published in English. All studies used a qualitative assessment of PET scans (abnormal FDG uptake with or without abnormal perfusion). Two studies assessed quantitative metrics (summed stress score in segments with abnormal FDG uptake, standardized uptake value and cardiac metabolic activity.) All studies reported major adverse cardiovascular events (MACE) as a composite outcome. After a mean follow up ranging from 1.4 to 4.1 years, there were a total of 105 MACE. All studies included death (either all-cause death or sudden cardiac death) and ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) as a component of MACE. Four of the six studies adjusted for several characteristics in their analysis. All four studies used left ventricular ejection fraction (LVEF). However, other adjustment variables were not consistent across studies. Five studies found a positive prognostic association with the primary outcome, two of which assessing right ventricular uptake. CONCLUSION: Although available evidence indicates FDG PET can be used in the risk stratification of patients with CS, our findings show further studies are needed to quantify the effect in this patient group.
引用
- Ahmed AI, Abebe AT, Han Y, et al. The prognostic role of cardiac positron emission tomography imaging in patients with sarcoidosis: A systematic review. J Nucl Cardiol. 2021. PMID: 34228337. doi:10.1007/s12350-021-02681-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。